Literature DB >> 15928252

Overexpression of immediate early genes in active Graves' ophthalmopathy.

Mikael Lantz1, Tereza Vondrichova, Hemang Parikh, Christofer Frenander, Martin Ridderstråle, Peter Asman, Magnus Aberg, Leif Groop, Bengt Hallengren.   

Abstract

CONTEXT: In Graves' ophthalmopathy a major problem is an increase in the intraorbital adipose tissue volume.
OBJECTIVE: The aim of this work was to define mechanisms of orbital adipogenesis.
DESIGN: This was an open-label prospective study.
SETTING: The study was conducted at the Clinic of Endocrinology, University Hospital. PARTICIPANTS: The study consisted of patients (n = 5) with severe ophthalmopathy with affection of the optic nerve and thyroid healthy controls (n = 5).
INTERVENTIONS: We performed lateral decompression of orbital tissue in patients unresponsive to corticosteroids and restorative surgery of the upper eyelid in thyroid healthy controls. MAIN OUTCOME MEASURE: We made large-scale measurements of gene expression, with microarray technique based on determination of fluorescence intensities in cases and controls.
RESULTS: A marker of adipose tissue, stearoyl-coenzyme A desaturase, was overexpressed in ophthalmopathy, and selection criteria were set to favor identification of genes known to be expressed in normal adipogenesis. The immediate early gene, cysteine-rich, angiogenic inducer, 61 (CYR61), was overexpressed in addition to 15 other immediate early genes (IEGs), and the expression of selected IEGs was confirmed with RT-PCR: CYR61, cyclooxygenase-2, dual-specificity phosphatase 1, B cell translocation gene 2, and early growth response 1. CYR61-responsive genes, known to participate in inflammation, IL-1beta, matrix metalloproteinase-3, and vascular endothelial growth factor were also overexpressed. Patients showed greater expression of CYR61 in the active than the chronic phase of ophthalmopathy, indicating that CYR61 is a marker of disease activity. Cyclooxygenase-2, the target gene of IL-1beta, was also overexpressed, although all patients had been treated with corticosteroids.
CONCLUSION: Adipocyte-related IEGs are overexpressed in active ophthalmopathy, and CYR61 may have a role in both orbital inflammation and adipogenesis and serve as a marker of disease activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15928252     DOI: 10.1210/jc.2004-2275

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

Review 1.  Graves' ophthalmopathy.

Authors:  Rebecca S Bahn
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

Review 2.  TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy.

Authors:  Terry J Smith
Journal:  Nat Rev Endocrinol       Date:  2015-01-06       Impact factor: 43.330

3.  Association of BTG2, CYR61, ZFP36, and SCD gene polymorphisms with Graves' disease and ophthalmopathy.

Authors:  Tereza Planck; Bushra Shahida; Marketa Sjögren; Leif Groop; Bengt Hallengren; Mikael Lantz
Journal:  Thyroid       Date:  2014-06-03       Impact factor: 6.568

Review 4.  Immunopathogenesis of Graves' ophthalmopathy: the role of the TSH receptor.

Authors:  Seethalakshmi Iyer; Rebecca Bahn
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2012-06       Impact factor: 4.690

Review 5.  Caught between a "Rho" and a hard place: are CCN1/CYR61 and CCN2/CTGF the arbiters of microvascular stiffness?

Authors:  Brahim Chaqour
Journal:  J Cell Commun Signal       Date:  2019-08-02       Impact factor: 5.782

6.  Adjuvant Treatment of Graves' Disease with Diclofenac: Safety, Effects on Ophthalmopathy and Antibody Concentrations.

Authors:  Mikael Lantz; Jan Calissendorff; Frank Träisk; Leif Tallstedt; Tereza Planck; Ove Törring; Bengt Hallengren; Peter Åsman
Journal:  Eur Thyroid J       Date:  2016-02-02

Review 7.  Molecular diagnosis: Implications for ophthalmology.

Authors:  James T Rosenbaum; Cailin H Sibley; Dongseok Choi; Christina A Harrington; Stephen R Planck
Journal:  Prog Retin Eye Res       Date:  2015-12-01       Impact factor: 21.198

8.  Improvement of thyroid eye disease following treatment with the cyclooxygenase-2 selective inhibitor celecoxib.

Authors:  Ajay E Kuriyan; Richard P Phipps; Charles W O'Loughlin; Steven E Feldon
Journal:  Thyroid       Date:  2008-08       Impact factor: 6.568

Review 9.  Liposuction Treatment of Lymphedema.

Authors:  Mark V Schaverien; D Alex Munnoch; Håkan Brorson
Journal:  Semin Plast Surg       Date:  2018-04-09       Impact factor: 2.314

10.  Transcriptome-level microarray expression profiling implicates IGF-1 and Wnt signalling dysregulation in the pathogenesis of thyroid-associated orbitopathy.

Authors:  Daniel G Ezra; Jonathan Krell; Geoffrey E Rose; Maryse Bailly; Justin Stebbing; Leandro Castellano
Journal:  J Clin Pathol       Date:  2012-05-03       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.